Industry Outlook: Mixed Signals Lead to a New Outsourcing Equation - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Industry Outlook: Mixed Signals Lead to a New Outsourcing Equation
Survey results indicate a healthy market, but increasing competition.

Pharmaceutical Technology

Chad Baker, Thomas Northcut, Tom Grill/Getty Images
If the respondents to this year's PharmSource—Pharmaceutical Technology Outsourcing Survey are right, 2008 is shaping up to be another strong year for the contract services industry and another big step in the remaking of the biopharmaceutical/pharmaceutical business model. However, the coming months are likely to be more difficult for contract service providers than have the past three years.

Figure 1
Industry trends in 2008 as reported by our respondents (see sidebar, "Respondents profile") are very similar to what we found in 2007. Nearly 45% of bio/pharma company respondents expect their spending on contract services to increase by 10% or more in 2008, about the same as in 2007 (see Figure 1). More than a quarter of these buy-side respondents say their contract services spend is growing faster than total spending in their functional area, but an equal number said spending is growing at a slower rate than total spend (see Figure 2). Still, respondents indicate that more activity is being outsourced than in past years: 42% say one quarter or more of the work in their functional area is being outsourced, up from 35% in 2007 (see Figure 3). Responses indicate that the rate of growth in outsourcing spend is slower at mid-size and generic bio/pharma companies than it is at large and small bio/pharma companies.

Figure 2
Responses from contract service providers reflect the optimism inherent in the buy-side responses. More than 65% of contractor respondents say they expect their revenues to increase by 10% or more in 2008, including a big jump in the number expecting growth of 20% or better (see Figure 4). Small bio/pharma companies are the most common source of new business for service providers, with 43% of contractor respondents citing them as their fastest growing segment. All market segments are contributing to contractor growth: 19% say Big Pharma is their fastest growing segment, 13% cite specialty pharma, and 17% say all segments are growing about the same.

Figure 3
Although major pharmaceutical companies aren't the fastest growing segment for most service providers, they are critical to the financial health of nearly all of them. Among contractor respondents, 38% say half or more of their revenue comes from Big Pharma, and another quarter say Big Pharma accounts for 25–49% of their revenue.

Intensifying competition

Survey responses indicate that bio/pharma companies are more open to using new vendors than they have been in recent years. In the 2008 survey, 43% of respondents said they are consolidating their vendor base or have plans to do so in the next two years; this statistic is down sharply from 57% in the 2007 outsourcing survey. One quarter of 2008 respondents say they have no plans to increase or consolidate their vendor base.


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Source: Pharmaceutical Technology,
Click here